we have studied the effect of the combination of a sulfonylurea ( hb 420 or glibenclamide ) with insulin in 22 type ii diabetic patients , treated with insulin and with residual insulin secretion ( fasting plasma c peptide level greater than 0.2 pmol/ml ) .
C0038766
sulfonylurea
C0017628
glibenclamide